Zoetis Inc. (NYSE:ZTS ) Stifel 2025 Jaws & Paws Conference May 29, 2025 9:10 AM ET Company Participants Wetteny Joseph - Chief Financial Officer Conference Call Participants Jon Block - Stifel Jon Block Great. Thank you.
Zoetis (ZTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The average of price targets set by Wall Street analysts indicates a potential upside of 26.2% in Zoetis (ZTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Ms. Kristin C. Peck CEO | XMIL Exchange | US98978V1035 ISIN |
US Country | 13,800 Employees | 18 Jul 2025 Last Dividend | - Last Split | 1 Feb 2013 IPO Date |